246 related articles for article (PubMed ID: 28465528)
1. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
Yu J; Chen L; Chen Y; Hasan MK; Ghia EM; Zhang L; Wu R; Rassenti LZ; Widhopf GF; Shen Z; Briggs SP; Kipps TJ
Leukemia; 2017 Dec; 31(12):2608-2614. PubMed ID: 28465528
[TBL] [Abstract][Full Text] [Related]
2. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
Hasan MK; Yu J; Widhopf GF; Rassenti LZ; Chen L; Shen Z; Briggs SP; Neuberg DS; Kipps TJ
Blood; 2018 Jul; 132(2):170-178. PubMed ID: 29678828
[TBL] [Abstract][Full Text] [Related]
3. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
[TBL] [Abstract][Full Text] [Related]
4. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Yu J; Chen L; Cui B; Widhopf Ii GF; Rassenti L; Shen Z; Briggs SP; Kipps TJ
Leukemia; 2017 Dec; 31(12):2615-2622. PubMed ID: 28465529
[TBL] [Abstract][Full Text] [Related]
5. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
Hasan MK; Rassenti L; Widhopf GF; Yu J; Kipps TJ
Leukemia; 2019 Mar; 33(3):653-661. PubMed ID: 30568170
[TBL] [Abstract][Full Text] [Related]
6. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
Hasan MK; Ghia EM; Rassenti LZ; Widhopf GF; Kipps TJ
Leukemia; 2021 Jun; 35(6):1621-1630. PubMed ID: 33097837
[TBL] [Abstract][Full Text] [Related]
7. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
[TBL] [Abstract][Full Text] [Related]
8. Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia.
Janovska P; Poppova L; Plevova K; Plesingerova H; Behal M; Kaucka M; Ovesna P; Hlozkova M; Borsky M; Stehlikova O; Brychtova Y; Doubek M; Machalova M; Baskar S; Kozubik A; Pospisilova S; Pavlova S; Bryja V
Clin Cancer Res; 2016 Jan; 22(2):459-69. PubMed ID: 26240275
[TBL] [Abstract][Full Text] [Related]
9. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.
Chen Y; Chen L; Yu J; Ghia EM; Choi MY; Zhang L; Zhang S; Sanchez-Lopez E; Widhopf GF; Messer K; Rassenti LZ; Jamieson C; Kipps TJ
Blood; 2019 Sep; 134(13):1084-1094. PubMed ID: 31409670
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.
Choi MY; Widhopf GF; Ghia EM; Kidwell RL; Hasan MK; Yu J; Rassenti LZ; Chen L; Chen Y; Pittman E; Pu M; Messer K; Prussak CE; Castro JE; Jamieson C; Kipps TJ
Cell Stem Cell; 2018 Jun; 22(6):951-959.e3. PubMed ID: 29859176
[TBL] [Abstract][Full Text] [Related]
11. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.
Rozovski U; Harris DM; Li P; Liu Z; Jain P; Ferrajoli A; Burger JA; Bose P; Thompson PA; Jain N; Wierda WG; Uziel O; Keating MJ; Estrov Z
J Immunol; 2019 Dec; 203(11):3078-3085. PubMed ID: 31645416
[TBL] [Abstract][Full Text] [Related]
12. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
Cui B; Ghia EM; Chen L; Rassenti LZ; DeBoever C; Widhopf GF; Yu J; Neuberg DS; Wierda WG; Rai KR; Kay NE; Brown JR; Jones JA; Gribben JG; Frazer KA; Kipps TJ
Blood; 2016 Dec; 128(25):2931-2940. PubMed ID: 27815263
[TBL] [Abstract][Full Text] [Related]
13. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
Ghia EM; Rassenti LZ; Choi MY; Quijada-Álamo M; Chu E; Widhopf GF; Kipps TJ
Leukemia; 2022 Jun; 36(6):1609-1618. PubMed ID: 35418613
[TBL] [Abstract][Full Text] [Related]
14.
Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
[TBL] [Abstract][Full Text] [Related]
15. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
16. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
17. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.
Li P; Harris D; Liu Z; Liu J; Keating M; Estrov Z
PLoS One; 2010 Jul; 5(7):e11859. PubMed ID: 20686606
[TBL] [Abstract][Full Text] [Related]
18. Wnt5a/ROR1 activates DAAM1 and promotes the migration in osteosarcoma cells.
Dai B; Shen Y; Yan T; Zhang A
Oncol Rep; 2020 Feb; 43(2):601-608. PubMed ID: 31894282
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways.
Karvonen H; Barker H; Kaleva L; Niininen W; Ungureanu D
Cells; 2019 Aug; 8(8):. PubMed ID: 31382410
[TBL] [Abstract][Full Text] [Related]
20. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma.
Yu J; Chen Y; Chen L; Zhang L; Rassenti LZ; Widhopf GF; Kipps TJ
Oncotarget; 2018 May; 9(37):24731-24736. PubMed ID: 29872501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
